<DOC>
	<DOCNO>NCT00862706</DOCNO>
	<brief_summary>The purpose study investigate efficacy telbivudine Blacks/African Americans Hispanics/Latinos compensate chronic hepatitis B 52 week treatment</brief_summary>
	<brief_title>Efficacy Telbivudine Blacks/African Americans Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must give write informed consent assessment perform . 2 . Male female , 16 70 year age . 3 . Black/African American race and/or Hispanic/Latino ethnicity 4 . Documented compensate chronic hepatitis B define follow : Clinical history compatible compensate chronic hepatitis B . Positive serum HBsAg least 6 month prior study entry HBeAgpositive HBeAgnegative Screening visit . Detectable serum HBsAg Screening visit . Serum ALT level &gt; = 1.3 &lt; 10x ULN Screening visit . 5 . Serum HBV DNA level &gt; = 5 log10 copies/mL determine COBAS™ Amplicor HBV PCR assay central study laboratory 6 . Willing able comply study drug regimen study requirement . Exclusion criterion : 1 . Subject pregnant breastfeeding . Women childbearing potential must negative serum betahuman chorionic gonadotropin ( βHCG ) Screening . 2 . Subject reproductive potential ( men woman ) unwilling use double barrier method contraception . It require double barrier method contraception use ( i.e . condom spermicide diaphragm spermicide ) subject reproductive potential ( men woman ) regardless whether hormonal agent also use method contraception . 3 . Subject coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , human immunodeficiency virus ( HIV1 HIV2 ) . Patients tested antibody HCV , HDV , HIV Screening visit assessment perform central laboratory . 4 . Subject previously receive lamivudine , adefovir dipivoxil , entecavir , telbivudine investigational antiHBV nucleoside nucleotide analog time . Precluded therapy include , limited , follow : previous exposure lamivudine , adefovir PMEA analog ( tenofovir , MCC478 ) , lobucavir , entecavir , emtricitabine ( FTC ) , LFMAU , LFd4C , investigational antiHBV nucleosides/nucleotides . 5 . Subject receive interferon immunomodulatory treatment HBV infection 12 month Screening study . Precluded therapy include , limited , interferon agent ( alpha , beta gammainterferons ) , thymosin , IL12 , putative systemic immunomodulators . 6 . Subject history clinical signs/symptoms hepatic decompensation ascites , variceal bleeding , hepatic encephalopathy , spontaneous bacterial peritonitis . 7 . Subject medical condition require prolonged frequent use systemic acyclovir famciclovir ( e.g. , recurrent herpes virus infection , etc ) . Prolonged use mean episodic treatment agent period exceed 10 day every 3 month , chronic suppressive therapy . 8 . Subject history hepatocellular carcinoma ( HCC ) finding suggestive possible HCC , suspicious focus image study elevate serum alphafetoprotein ( AFP ) level . In patient finding , HCC must ruledout prior Screening present study . 9 . Subject one additional know primary secondary cause liver disease , hepatitis B ( e.g. , alcoholism , autoimmune hepatitis , malignancy hepatic involvement , hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's Disease , congenital metabolic condition affect liver , congestive heart failure severe cardiopulmonary disease , etc. ) . Gilbert 's syndrome DubinJohnson syndrome , two benign disorder associate lowgrade hyberbilirubinemia , exclude patient participation trial . 10 . Subject history clinical laboratory evidence pancreatitis demonstrate clinical laboratory course consistent pancreatitis within 12 week study screen . 11 . Subject currently abuse alcohol illicit drug , history alcohol abuse illicit substance abuse within precede two year . For purpose present study , alcohol abuse arbitrarily define frequent consumption alcoholic beverage average daily intake 40g ethanol 3 beer equivalent . Patients currently methadone maintenance treatment program NOT eligible study due potential interference study evaluation . 12 . Subject medical condition require frequent prolong use systemic corticosteroid ( e.g. , severe asthma , severe arthritis autoimmune condition , organ transplantation , adrenal insufficiency , etc ) . 13 . Subject concurrent medical social condition likely preclude compliance schedule evaluation protocol , likely confound efficacy safety observation study ( e.g. , concurrent malignancy ; history unstable angina repeat myocardial infarction ; uncontrolled asthma diabetes ; unstable thyroid disease significant hormonal condition ; frequent uncontrolled seizure disorder ; severe psychiatric disorder require psychotropic medication ; active tuberculosis , pneumonia , severe infection current treatment ; live country investigative site ; medical social circumstance likely interfere schedule evaluation ) . 14 . A history treat malignancy ( hepatocellular carcinoma ) allowable subject 's malignancy complete remission , chemotherapy without additional surgical intervention , precede 3 year . 15 . Subject history myopathy , myositis , persistent muscle weakness peripheral neuropathy ( polyneuropathy ) . 16 . Subject known history allergy nucleoside analogue . 17 . Subject enrol plan enroll another clinical trial investigational agent participate study . 18 . Subject follow laboratory value Screening : Absolute neutrophil count ( ANC ) &lt; 1500/mm3 Hemoglobin &lt; 11.0 g/dL ( men ) &lt; 10.0 g/dL ( woman ) Platelet count &lt; 75,000/mm3 ALT ( SGPT ) &gt; 10x ULN Serum creatinine &gt; 1.5x ULN Total bilirubin &gt; 2.0x mg/dL Prothrombin time &gt; 2.0 second ULN Serum amylase lipase &gt; = 1.5x ULN Serum albumin &lt; 3.3 g/dL Serum alphafetoprotein ( AFP ) &gt; 50 ng/mL . If AFP &gt; 50 ng/mL , subject must image study liver demonstrate evidence tumor within 60 day prior study entry . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic HBV</keyword>
</DOC>